论文部分内容阅读
[目的]探讨局部晚期宫颈癌年轻患者在术前经不同给药途径新辅助化疗后对术后卵巢功能的影响。[方法]选取2014年7月至2015年12月局部晚期宫颈癌年轻患者70例为研究对象,按照随机数字法则分为两组,其中动脉化疗组38例,静脉化疗组32例,两组患者均在术前采取TP化疗方案,术后进行BOMP化疗方案,比较两组手术前后卵泡刺激素(FSH)、血清雌二醇(E2)、黄体生成素(LH)变化以评估对卵巢功能的影响。[结果 ]与术前及术后1个月对比,动脉化疗组患者在术后6个月FSH水平显著性降低,E2水平显著性升高(P<0.05),LH水平无显著性变化;静脉化疗组患者手术前后FSH、E2及LH水平均无显著性变化(P>0.05)。动脉治疗组术后3个月排卵功能恢复16例,占42.11%,静脉化疗组术后3个月排卵功能恢复13例,占40.63%,两组对比差异无统计学意义(P<0.05)。[结论]经动脉介入栓塞化疗与静脉化疗对年轻局部晚期宫颈癌患者的卵巢功能的远期影响无显著性差异,均可用于局部晚期宫颈癌的治疗。
[Objective] To investigate the effect of neoadjuvant chemotherapy on ovarian function in young patients with locally advanced cervical cancer before and after different administration routes. [Methods] Seventy patients with locally advanced cervical cancer from July 2014 to December 2015 were divided into two groups according to the rule of random number, including 38 patients in arterial chemotherapy group, 32 patients in intravenous chemotherapy group and 32 patients in both groups All patients underwent preoperative chemotherapy with TP and postoperative chemotherapy with BOMP. The changes of follicle stimulating hormone (FSH), serum estradiol (E2) and luteinizing hormone (LH) before and after operation were compared to evaluate the effect on ovarian function . [Results] Compared with preoperative and postoperative one month, the patients in arterial chemotherapy group had significantly lower FSH level, significantly increased E2 level (P <0.05) and no significant change in LH level at 6 months after operation. The levels of FSH, E2 and LH in the chemotherapy group had no significant changes before and after surgery (P> 0.05). In the arterial group, ovulation recovery was 16 cases (42.11%) at 3 months and 13 cases (40.63%) at 3 months after operation. There was no significant difference between the two groups (P <0.05). [Conclusion] The long-term effect of transcatheter arterial chemoembolization and intravenous chemotherapy on ovarian function in patients with locally advanced cervical cancer has no significant difference, which can be used for the treatment of locally advanced cervical cancer.